S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

Biogen News Headlines (NASDAQ:BIIB)

$278.82
-3.05 (-1.08 %)
(As of 10/23/2019 04:00 PM ET)
Today's Range
$275.66
Now: $278.82
$286.67
50-Day Range
$217.39
MA: $230.88
$286.54
52-Week Range
$215.77
Now: $278.82
$344.00
Volume5.54 million shs
Average Volume1.92 million shs
Market Capitalization$51.43 billion
P/E Ratio10.64
Dividend YieldN/A
Beta1.02

Headlines

Biogen (NASDAQ BIIB) News Headlines

Source:
DateHeadline
Why Biogen Stock Is on Fire Today - Motley FoolWhy Biogen Stock Is on Fire Today - Motley Fool
www.fool.com - October 23 at 6:45 PM
Drugmaker Alkermes cuts 160 jobs in effort to lower expensesDrugmaker Alkermes cuts 160 jobs in effort to lower expenses
finance.yahoo.com - October 23 at 6:45 PM
Biogen Alzheimer’s Revival Wins New Believers, Yet Doubts Linger - BloombergBiogen Alzheimer’s Revival Wins New Believers, Yet Doubts Linger - Bloomberg
www.bloomberg.com - October 23 at 1:44 PM
Biogen CEO reasonably confident once-doomed Alzheimers drug will be granted FDA approval - CNBCBiogen CEO 'reasonably confident' once-doomed Alzheimer's drug will be granted FDA approval - CNBC
www.cnbc.com - October 23 at 1:44 PM
Is Biogen Stock A Buy After Rocketing On A New Analysis In Alzheimer's?Is Biogen Stock A Buy After Rocketing On A New Analysis In Alzheimer's?
finance.yahoo.com - October 23 at 1:44 PM
JPMorgan Chase & Co. Boosts Biogen (NASDAQ:BIIB) Price Target to $260.00JPMorgan Chase & Co. Boosts Biogen (NASDAQ:BIIB) Price Target to $260.00
www.americanbankingnews.com - October 23 at 11:47 AM
Canaccord Genuity Raises Biogen (NASDAQ:BIIB) Price Target to $305.00Canaccord Genuity Raises Biogen (NASDAQ:BIIB) Price Target to $305.00
www.americanbankingnews.com - October 23 at 11:47 AM
Biogen (NASDAQ:BIIB) Price Target Raised to $260.00 at Credit Suisse GroupBiogen (NASDAQ:BIIB) Price Target Raised to $260.00 at Credit Suisse Group
www.americanbankingnews.com - October 23 at 11:47 AM
Cowen Boosts Biogen (NASDAQ:BIIB) Price Target to $325.00Cowen Boosts Biogen (NASDAQ:BIIB) Price Target to $325.00
www.americanbankingnews.com - October 23 at 10:39 AM
Biogen (NASDAQ:BIIB) Given New $262.00 Price Target at Morgan StanleyBiogen (NASDAQ:BIIB) Given New $262.00 Price Target at Morgan Stanley
www.americanbankingnews.com - October 23 at 10:39 AM
Biogen (NASDAQ:BIIB) Upgraded to Outperform by Svb LeerinkBiogen (NASDAQ:BIIB) Upgraded to Outperform by Svb Leerink
www.americanbankingnews.com - October 23 at 10:39 AM
Biogen (NASDAQ:BIIB) Posts Quarterly  Earnings Results, Beats Expectations By $0.90 EPSBiogen (NASDAQ:BIIB) Posts Quarterly Earnings Results, Beats Expectations By $0.90 EPS
www.americanbankingnews.com - October 23 at 9:43 AM
BMO Capital Markets Boosts Biogen (NASDAQ:BIIB) Price Target to $297.00BMO Capital Markets Boosts Biogen (NASDAQ:BIIB) Price Target to $297.00
www.americanbankingnews.com - October 23 at 9:37 AM
Biogen soars as it seeks U.S. Alzheimer’s drug approval - Yahoo FinanceBiogen soars as it seeks U.S. Alzheimer’s drug approval - Yahoo Finance
finance.yahoo.com - October 23 at 8:43 AM
D.E. Shaw, Arrowstreet Bets Pay Off With Biogen Drug Revival - BloombergD.E. Shaw, Arrowstreet Bets Pay Off With Biogen Drug Revival - Bloomberg
www.bloomberg.com - October 23 at 8:43 AM
Is Biogen a Buy After the Biggest Biotech Bombshell in Years? - Motley FoolIs Biogen a Buy After the Biggest Biotech Bombshell in Years? - Motley Fool
www.fool.com - October 23 at 8:43 AM
Biogen Alzheimer’s Revival Wins New Believers, Yet Doubts LingerBiogen Alzheimer’s Revival Wins New Believers, Yet Doubts Linger
finance.yahoo.com - October 23 at 8:43 AM
Guggenheim Upgrades Biogen (NASDAQ:BIIB) to "Buy"Guggenheim Upgrades Biogen (NASDAQ:BIIB) to "Buy"
www.americanbankingnews.com - October 23 at 8:07 AM
HC Wainwright Raises Biogen (NASDAQ:BIIB) Price Target to $335.00HC Wainwright Raises Biogen (NASDAQ:BIIB) Price Target to $335.00
www.americanbankingnews.com - October 23 at 8:05 AM
Leerink Swann Upgrades Biogen (NASDAQ:BIIB) to OutperformLeerink Swann Upgrades Biogen (NASDAQ:BIIB) to Outperform
www.americanbankingnews.com - October 23 at 8:05 AM
Biogen Target of Unusually High Options Trading (NASDAQ:BIIB)Biogen Target of Unusually High Options Trading (NASDAQ:BIIB)
www.americanbankingnews.com - October 23 at 7:44 AM
Biogen Bombshell Triggers Annual-High Options Volume - Yahoo FinanceBiogen Bombshell Triggers Annual-High Options Volume - Yahoo Finance
finance.yahoo.com - October 23 at 3:42 AM
Biogen Alzheimer’s Drug Is Far From Done Deal, Wall Street Says - BloombergBiogen Alzheimer’s Drug Is Far From Done Deal, Wall Street Says - Bloomberg
www.bloomberg.com - October 23 at 3:42 AM
Biogen, Eisai revive plans for Alzheimer's drug, surprising marketBiogen, Eisai revive plans for Alzheimer's drug, surprising market
uk.finance.yahoo.com - October 23 at 3:42 AM
Somewhat Favorable News Coverage Extremely Likely to Impact Biogen (NASDAQ:BIIB) Stock PriceSomewhat Favorable News Coverage Extremely Likely to Impact Biogen (NASDAQ:BIIB) Stock Price
www.americanbankingnews.com - October 23 at 3:14 AM
The Dow Is Drifting, While Biogen Soars After Upbeat Earnings - BarronsThe Dow Is Drifting, While Biogen Soars After Upbeat Earnings - Barron's
www.barrons.com - October 22 at 7:20 PM
Biogen resurrects Alzheimers drug; shares jump 37% - ReutersBiogen resurrects Alzheimer's drug; shares jump 37% - Reuters
www.reuters.com - October 22 at 7:20 PM
Biogen (BIIB) Up 40% on Alzheimers Drug & More - Yahoo FinanceBiogen (BIIB) Up 40% on Alzheimer's Drug & More - Yahoo Finance
finance.yahoo.com - October 22 at 7:20 PM
Biogen resurrects Alzheimers drug; shares jump 27% - ReutersBiogen resurrects Alzheimer's drug; shares jump 27% - Reuters
www.reuters.com - October 22 at 7:20 PM
Biogen Inc. (BIIB) CEO Michel Vounatsos on Q3 2019 Results - Earnings Call TranscriptBiogen Inc. (BIIB) CEO Michel Vounatsos on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - October 22 at 4:53 PM
Biogen reanalyzes studies, presses ahead on Alzheimers drugBiogen reanalyzes studies, presses ahead on Alzheimer's drug
marketbeat.com - October 22 at 4:30 PM
UBS Group Increases Biogen (NASDAQ:BIIB) Price Target to $334.00UBS Group Increases Biogen (NASDAQ:BIIB) Price Target to $334.00
www.americanbankingnews.com - October 22 at 2:52 PM
Biogen (NASDAQ:BIIB) Rating Reiterated by Stifel NicolausBiogen (NASDAQ:BIIB) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - October 22 at 2:52 PM
Biogen (NASDAQ:BIIB) Price Target Increased to $310.00 by Analysts at Jefferies Financial GroupBiogen (NASDAQ:BIIB) Price Target Increased to $310.00 by Analysts at Jefferies Financial Group
www.americanbankingnews.com - October 22 at 2:52 PM
Cramer: Biogens Alzheimers treatment would be the biggest drug ever - CNBCCramer: Biogen's Alzheimer's treatment would be 'the biggest drug ever' - CNBC
www.cnbc.com - October 22 at 2:20 PM
Biogen’s stock blasts off after surprise reversal on Alzheimer’s drug, earnings beatBiogen’s stock blasts off after surprise reversal on Alzheimer’s drug, earnings beat
www.marketwatch.com - October 22 at 11:12 AM
Biogen (NASDAQ:BIIB) Rating Reiterated by CowenBiogen (NASDAQ:BIIB) Rating Reiterated by Cowen
www.americanbankingnews.com - October 22 at 9:33 AM
Company says it will seek approval of Alzheimers drugCompany says it will seek approval of Alzheimer's drug
marketbeat.com - October 22 at 9:29 AM
Biogen (NASDAQ:BIIB) Earns Hold Rating from MizuhoBiogen (NASDAQ:BIIB) Earns Hold Rating from Mizuho
www.americanbankingnews.com - October 22 at 8:41 AM
Biogen Earnings, Revenue Beat in Q3 - Yahoo FinanceBiogen Earnings, Revenue Beat in Q3 - Yahoo Finance
finance.yahoo.com - October 22 at 7:57 AM
Neurimmune Welcomes Biogens News on Clinical Benefit of Aducanumab - PRNewswireNeurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab - PRNewswire
www.prnewswire.com - October 22 at 7:57 AM
Form 8-K BIOGEN INC. For: Oct 22 - StreetInsider.comForm 8-K BIOGEN INC. For: Oct 22 - StreetInsider.com
www.streetinsider.com - October 22 at 7:57 AM
Biogen says it will pursue FDA approval of early Alzheimers drug - MarketWatchBiogen says it will pursue FDA approval of early Alzheimer's drug - MarketWatch
www.marketwatch.com - October 22 at 7:57 AM
Biogen resurrects Alzheimers drug; shares jump 35% - ReutersBiogen resurrects Alzheimer's drug; shares jump 35% - Reuters
www.reuters.com - October 22 at 7:57 AM
Biogen Surges After Announcing Plans to Pursue Alzheimer's Drug ApprovalBiogen Surges After Announcing Plans to Pursue Alzheimer's Drug Approval
finance.yahoo.com - October 22 at 7:57 AM
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 StudiesBiogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
finance.yahoo.com - October 22 at 7:57 AM
Biogen says it will pursue FDA approval of early Alzheimer's drugBiogen says it will pursue FDA approval of early Alzheimer's drug
finance.yahoo.com - October 22 at 7:57 AM
Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval processBiogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process
finance.yahoo.com - October 22 at 7:57 AM
Biogen to seek Alzheimer’s drug approvalBiogen to seek Alzheimer’s drug approval
finance.yahoo.com - October 22 at 7:57 AM
Biogen Surges as Momentum for Alzheimer’s Treatment Revives HopeBiogen Surges as Momentum for Alzheimer’s Treatment Revives Hope
finance.yahoo.com - October 22 at 7:57 AM
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel